Natco Pharma
![]() | |
Traded as | NSE: NATCOPHARM BSE: 524816 |
---|---|
Industry | Pharmaceuticals |
Founded | 1981 |
Founder(s)s | VC Nannapaneni |
Headquarters | , |
Area served | Global |
Key people | VC Nannapaneni (Chairman and MD)[1] Rajeev Nannapaneni (CEO and Vice Chairman)[2] |
Website | natcopharma.co.in |
Natco Pharma is an Indian pharmaceutical company based in Hyderabad, which makes finished dosage formulations and active pharmaceutical ingredients. It is the market leader in branded oncology medicines in India,[3] and among the country's top three producers of hepatitis C drugs.[4]
In 2003, Natco Pharma launched Veenat, a generic version of Novartis AG's anti-cancer drug Glivec. It won the subsequent patent protection legal battle against Novartis in 2013.[5] In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[4] In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide at a 98% discount to the drug's selling price in the United States.[6]
In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[5]
References
- ↑ "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
- ↑ "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
- ↑ "Natco Pharma lines up 20 `Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
- ↑ 4.0 4.1 "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
- ↑ 5.0 5.1 "Niche Play". Business Today. Retrieved 19 April 2020.
- ↑ "Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price – Business News , Firstpost". Firstpost. 10 May 2017. Retrieved 31 July 2020.